33.3
Bristol-Myers Squibb Company
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
Assets
(positive)
Change from FY21 to FY25
billions USD
FY21:
FY22:
27.3
FY23:
31.8
FY24:
29.8
FY25:
29.4
(positive)
Change from FY21 to FY25
billions USD
FY21:
76.1
FY22:
69.5
FY23:
63.4
FY24:
62.8
FY25:
60.6
Total assets
Change from FY21 to FY25
billions USD
FY21:
109
FY22:
96.8
FY23:
95.2
FY24:
92.6
FY25:
90.0
Liabilities & Equity
(negative)
Change from FY21 to FY25
billions USD
FY21:
21.9
FY22:
21.9
FY23:
22.3
FY24:
23.8
FY25:
23.4
(negative)
Change from FY21 to FY25
billions USD
FY21:
51.4
FY22:
43.8
FY23:
43.4
FY24:
52.4
FY25:
48.1
(positive)
Change from FY21 to FY25
billions USD
FY21:
35.9
FY22:
31.1
FY23:
29.4
FY24:
16.3
FY25:
18.5
Total liabilities & equity
Change from FY21 to FY25
billions USD
FY21:
109
FY22:
96.8
FY23:
95.1
FY24:
92.6
FY25:
90.0
All amounts in billions USD